Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combination of Chemotherapy and Gefitinib as First-line Treatment of Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomised Controlled Trial

Trial Profile

Combination of Chemotherapy and Gefitinib as First-line Treatment of Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomised Controlled Trial

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gefitinib (Primary) ; Carboplatin; Pemetrexed
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Sep 2019 Results (data cut off Sep 28 2018) assessing overall survival presented at the 20th World Conference on Lung Cancer
    • 15 Sep 2017 Results assessing efficacy of combination of pemetrexed plus carboplatin and gefitinib in patients with non small cell lung cancer, were published in the International Journal of Cancer.
    • 19 Apr 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top